Literature DB >> 7042774

Mechanism of lesion production in pemphigus and pemphigoid.

W M Sams, W R Gammon.   

Abstract

Current evidence strongly supports the theory that the lesions of pemphigus are due to binding of pemphigus antibody to an antigen in or near the epidermal cell membrane, which causes a release of at least one enzyme which results in dissolution of the intercellular attachments and acantholysis. Similarly, strong evidence supports the hypothesis that pemphigoid blisters are due to binding of antibody at the basement membrane, followed by activation of complement and release of anaphylatoxins which activate tissue mast cells to release eosinophil chemotactic factor. These eosinophils then release tissue-destructive enzymes and reactive oxygen intermediates directly onto the basement membrane zone, with loss of dermoepidermal adherence and formation of blisters.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7042774     DOI: 10.1016/s0190-9622(82)70036-2

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  13 in total

1.  Pemphigus and pemphigoid in domestic animals: an overview.

Authors:  L J Ackerman
Journal:  Can Vet J       Date:  1985-06       Impact factor: 1.008

2.  Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins.

Authors:  L Borrego; B Maynard; E A Peterson; T George; L Iglesias; M S Peters; W Newman; G J Gleich; K M Leiferman
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

3.  Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies.

Authors:  J R Stanley; T Tanaka; S Mueller; V Klaus-Kovtun; D Roop
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

4.  Eosinophil infiltration in three patients with generalized atrophic benign epidermolysis bullosa from a Japanese family: molecular genetic and immunohistochemical studies.

Authors:  Masayo Nomura; Yoh-Ichiro Hamasaki; Ichiro Katayama; Kuniko Abe; Norio Niikawa; Koh-Ichiro Yoshiura
Journal:  J Hum Genet       Date:  2005-09-20       Impact factor: 3.172

5.  Dexamethasone-induced plasminogen activator inhibitor: characterization, purification, and preparation of monoclonal antibodies.

Authors:  A Oikarinen; M Höyhtyä; M Järvinen
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

6.  Human autoantibodies against the 230-kD bullous pemphigoid antigen (BPAG1) bind only to the intracellular domain of the hemidesmosome, whereas those against the 180-kD bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the hemidesmosome in normal human and swine skin.

Authors:  A Ishiko; H Shimizu; A Kikuchi; T Ebihara; T Hashimoto; T Nishikawa
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

7.  The role of complement in experimental bullous pemphigoid.

Authors:  Z Liu; G J Giudice; S J Swartz; J A Fairley; G O Till; J L Troy; L A Diaz
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

8.  Acantholysis produced in vitro with pemphigus serum: hydrocortisone inhibits acantholysis, while dapsone and 6-mercaptopurine do not inhibit acantholysis.

Authors:  E W Jeffes; R P Kaplan; A R Ahmed
Journal:  J Clin Immunol       Date:  1984-09       Impact factor: 8.317

9.  High doses of antigen-nonspecific IgG do not inhibit pemphigus acantholysis in skin organ cultures.

Authors:  T Hunziker; U E Nydegger; P J Späth; H A Gerber; M Hess; U Wiesmann; A Krebs
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

Review 10.  Pemphigus autoimmunity: hypotheses and realities.

Authors:  Sergei A Grando
Journal:  Autoimmunity       Date:  2011-09-23       Impact factor: 2.815

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.